EMD Serono Exclusive Supporter of Newly Launched Multiple Sclerosis Resource
ROCKLAND, Mass., Oct. 1, 2013
ROCKLAND, Mass., Oct. 1, 2013 /PRNewswire/ --EMD Serono, Inc., a subsidiary
of Merck KGaA, Darmstadt, Germany, is the founding supporter of the newly
launched Multiple Sclerosis (MS) Resource Centre website
(http://multiplesclerosis.elsevierresource.com/) developed by Elsevier, B.V.
of the Netherlands. EMD Serono helped established the MS Resource Centre
through a $250,000 unrestricted grant to Elsevier, B.V. to develop and launch
the website, which will provide high quality, balanced and scientifically
valid information to health care providers.
"EMD Serono is proud to have provided the necessary foundation for Elsevier to
develop this website that aims to provide clinicians with access to the latest
literature on multiple sclerosis," said Thorsten Eickenhorst, MD, PhD, MBA,
Senior Vice President and Chief Medical Officer at EMD Serono, Inc. "EMD
Serono is committed to supporting organizations that invest in the
understanding and treatment of multiple sclerosis, and share our goal of
improving patient care."
The MS Resource Centre is a medical education platform for healthcare
providers hosted by Elsevier's new peer-reviewed journal, Multiple Sclerosis
and Related Disorders (http://www.msard-journal.com/). This website will
afford the MS community numerous benefits, including access to taped lectures,
video interviews with leaders in the field, a congress planner and key
articles reporting on breakthrough findings by highly regarded authors.
Timothy Vartanian, MD, PhD, Professor at the Brain and Mind Research Institute
and the Department of Neurology, Weill Cornell Medical College, Cornell
University is the Editor of the Resource Center.
The site will be launched at the ECTRIMS 2013 conference, October 2 – 5, in
Copenhagen, Denmark. For more information, congress delegates should stop by
the Elsevier Exhibit Booth at ECTRIMS.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader
in the US biopharmaceutical arena, integrating cutting-edge science with
unparalleled patient support systems to improve people's lives. The company
has strong market positions in neurodegenerative diseases, endocrinology and
in reproductive health. In addition, EMD Serono is growing its expertise and
presence in the area of oncology, with more than 15 projects currently in
development. With a clear focus on the patient and a leadership presence in
the biopharmaceutical industry, EMD Serono's US footprint continues to grow,
with approximately 1,000 employees around the country and fully integrated
commercial, clinical and research operations in the company's home state of
For more information, please visit www.emdserono.com
About Merck KGaA
Merck is a leading pharmaceutical, chemical and life science company with
total revenues of € 11.2 billion in 2012, a history that began in 1668, and a
future shaped by approx. 38,000 employees in 66 countries. Its success is
characterized by innovations from entrepreneurial employees. Merck's operating
activities come under the umbrella of Merck KGaA, in which the Merck family
holds an approximately 70% interest and free shareholders own the remaining
approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated
and has been an independent company ever since.
For more information, please visit www.merckserono.comor www.merckgroup.com
SOURCE EMD Serono
Contact: Erin-Marie Beals, 781-681-2850
Press spacebar to pause and continue. Press esc to stop.